Delivra Health Brands (DHB) AI Stock Analysis

• Market Cap: C$6.88M
• Dividend Yield: N/A
• Average Volume (3M): 7.66K
• Price to Earnings (P/E): 181.8
• Beta (1Y): 0.26
• Revenue Growth: 4.04%
• EPS Growth: 80.24%
• Country: CA
• Employees: 22
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 31,261,782
• 10 Day Avg. Volume: 3,578
• 30 Day Avg. Volume: 7,660
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.72
• Price Target Upside: 227.27% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 56 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Delivra Health Brands is in a recovery phase with improving financial metrics and strategic corporate actions. However, the poor valuation due to negative earnings and lack of dividends weigh heavily on the score. The technical analysis suggests neutral market sentiment, and corporate events are positive, indicating potential for future growth.

Delivra Health Brands Business Overview & Revenue Model

Company Description

Delivra Health Brands Inc. through its subsidiaries, provides lifestyle and wellness products to consumers and patients in regulated markets worldwide. The company is involved in selling of cannabis, liquid sleep shots, sleep powder packets, gummies, and pain relief creams. It offers its products under LivRelief, Dream Water, and LivRelief infused brand names. The company was formerly known as Harvest One Cannabis Inc. Delivra Health Brands Inc. is headquartered in Vancouver, Canada.

How the Company Makes Money

Delivra Health Brands generates revenue primarily through the sale of its topical products, which are distributed across various retail and online channels. The company capitalizes on its proprietary delivery systems to offer differentiated products that appeal to consumers seeking effective health and wellness solutions. Additionally, DHB may engage in strategic partnerships or licensing agreements with other companies to expand its market reach and enhance its product offerings. These collaborations can contribute to revenue generation by enabling access to new markets and customer segments.

Delivra Health Brands Financial Statement Overview

Summary

Delivra Health Brands is showing improving revenue and gross profit margins, with a 28.4% revenue growth rate and a gross profit margin of 47.2%. However, negative EBIT margins and low net profitability are concerns. The balance sheet is stable with a debt-to-equity ratio of 0.50, and cash flow improvements are positive, highlighting better operational efficiency.

Income Statement

Delivra Health Brands has shown positive trends in revenue growth, with an increase from $9.79M in 2023 to $12.57M in TTM, resulting in a 28.4% growth rate. The gross profit margin has improved significantly to 47.2% in TTM, indicating better cost management. However, the company is struggling with negative EBIT margins and thin net profit margins, which could be a concern for long-term profitability.

Balance Sheet

The balance sheet shows a relatively stable equity base with a debt-to-equity ratio of 0.50 in TTM, indicating modest leverage. The equity ratio stands at 50.9%, showing solid equity financing. However, the return on equity is minimal at 0.14%, reflecting the challenge in generating returns from equity capital.

Cash Flow

The cash flow statement highlights a positive trend in free cash flow, which increased from negative values to $407K in TTM. The operating cash flow to net income ratio is high, indicating strong cash generation relative to reported profits. The company needs to maintain this momentum to ensure liquidity and operational flexibility.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	12.60M	12.38M	9.79M	8.14M	7.96M	7.78M
Gross Profit	6.28M	6.40M	3.49M	485.00K	-297.00K	-1.62M
EBITDA	1.40M	2.35M	1.40M	-4.25M	-7.04M	-55.40M
Net Income	-134.00K	876.00K	-184.00K	-7.01M	-28.54M	-79.86M
Balance Sheet
Total Assets	8.61M	10.05M	10.56M	11.59M	19.06M	57.84M
Cash, Cash Equivalents and Short-Term Investments	3.49M	4.20M	2.73M	1.11M	5.14M	1.41M
Total Debt	2.23M	2.03M	1.96M	2.11M	2.16M	5.97M
Total Liabilities	4.40M	4.86M	7.17M	8.21M	9.09M	21.27M
Stockholders Equity	4.21M	5.19M	3.39M	3.37M	9.98M	33.52M
Cash Flow
Free Cash Flow	-513.00K	756.00K	-1.13M	-4.46M	-9.68M	-24.67M
Operating Cash Flow	-513.00K	756.00K	-1.09M	-4.44M	-9.65M	-18.36M
Investing Cash Flow	0.00	11.00K	2.91M	1.35M	12.27M	-3.64M
Financing Cash Flow	-88.00K	594.00K	-255.00K	-309.00K	446.00K	3.17M

Delivra Health Brands Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DHB, the sentiment is Positive. The current price of 0.22 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.21, and above the 200-day MA of 0.19, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.42 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DHB.

Delivra Health Brands Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHB	56 Neutral	C$6.88M	181.82	-3.45%	―	4.04%	80.24%
Sector *	51 Neutral	$7.46B	-0.25	-46.00%	2.25%	22.77%	-2.14%
ATLE	44 Neutral	C$63.40M	―	-971.43%	―	571.23%	64.25%
BBRRF	―	$7.17M	―	-112.06%	―	―	―
NDVAF	―	$4.29M	―		―	―	―
IMCC	46 Neutral	$8.21M	―	-36.94%	―	2.17%	88.34%
CANB	45 Neutral	C$5.95M	90.00	0.83%	―	-8.84%	-96.82%

Delivra Health Brands Corporate Events

Delivra Health Expands U.S. Reach Through QVC Partnership

Delivra Health Brands has expanded its U.S. presence by partnering with QVC, a major televised and online shopping network. This collaboration will enhance the distribution and visibility of its Dream Water Snoozeberry Sleep Shots, potentially increasing brand loyalty and consumer engagement through QVC’s unique shopping experience.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Brands Enhances Investor Relations with New Partnerships

Delivra Health Brands Inc. has engaged Global One Media and Bergskogar Limited for investor relations services to enhance its digital marketing and global business development efforts. These collaborations are expected to strengthen Delivra Health’s market presence and visibility, potentially impacting its operations and stakeholder interests positively.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Achieves Positive Q3 EBITDA Amid Strategic Marketing Push

Delivra Health Brands reported a positive adjusted EBITDA for the third quarter of fiscal 2025, driven by strong marketing momentum and growth in units sold. The company achieved a 3% year-over-year revenue increase and expanded its Dream Water product offerings in Canada, while also launching successful marketing campaigns for its LivRelief brand. Despite a reduction in gross profit margin due to higher costs, Delivra Health’s strategic investments in marketing and product innovation have laid a strong foundation for future growth.

The most recent analyst rating on (TSE:DHB) stock is a Buy with a C$0.09 price target. To see the full list of analyst forecasts on Delivra Health Brands stock, see the TSE:DHB Stock Forecast page.

Delivra Health Expands Dream Water® Brand with New Product Launch in Middle East

Delivra Health Brands Inc. is expanding its Dream Water® product line by launching 60-Count Sleep Gummies in the Middle Eastern markets through its Kuwait-based distributor. This strategic move is expected to enhance the brand’s presence and growth in new markets, leveraging the success of its sleep solutions in Canada and the U.S., and offering more choices to consumers in the region.